FINWIRES · TerminalLIVE
FINWIRES

HKG:2196

18 stories mentioning HKG:2196Updated 6d ago

Every FINWIRES story that references HKG:2196, newest first.

Asia

Fosun Pharma Unit Gets China Clinical Trial Approval for Parkinson's Drug

Shanghai Fosun Pharmaceutical's (HKG:2196) subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical received approval from China's National Medical Products Administration to conduct a clinical trial of DM1001 Formulation for the treatment of signs and symptoms of Parkinson's disease, according to a Friday Hong Kong bourse filing.The company plans to commence a Phase I clinical trial in China once relevant conditions are met.

HKG:2196
Asia

Fosun Pharma Unit Gets China Clinical Trial Approval for Triglyceride Drug Candidate

Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) said subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) received China's National Medical Products Administration approval to conduct a clinical trial for FXR0906, a drug candidate for hypertriglyceridemia.Fosun Pharma (Shenzhen) plans to start a Phase I clinical trial in mainland China after fulfilling relevant conditions, according to Wednesday Hong Kong bourse filing.Shanghai Fosun Pharma's shares rose nearly 2% in recent trade.

HKG:2196SHA:600196
Asia

Junshi Biosciences Licenses Autoimmune Drug to Fosun Pharma

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) agreed to license JS005 to Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) for the greater China region, according to a Wednesday filing with the Hong Kong bourse.The company will receive an upfront payment of 215 million yuan, plus a further 1.13 billion yuan in milestone-related payments.Junshi Biosciences will also receive royalty payments once the drug is commercialized in the greater China region.JS005, also known as roconkibart, is a treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis and ankylosing spondylitis.

HKG:1877HKG:2196SHA:600196SHA:688180
Asia

Fosun Pharma to Offload Partnership Fund Stake for 1 Million Yuan; Shares Down 4%

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) and a subsidiary agreed to dispose of their stake in Jinan Fujian Partnership to Shanghai Fujian, according to a Shanghai bourse filing on Tuesday.Fosun will transfer its subscribed 7 million yuan interest in the partnership fund for 1.1 million yuan, while its subsidiary, Fosun Pingyao, will transfer its 1 million yuan stake for 150,000 yuan.After the transaction, the company will no longer own any equity in Jinan Fujian.The pharmaceutical company's Hong Kong shares dropped 4%, while Shanghai shares fell nearly 2% during the afternoon trade.

HKG:2196SHA:600196
Asia

Fosun Pharma's Unit Gets Registration Nod for Spasm, Pain Drug in China

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) unit Hebei Wanbang Folon Pharmaceutical obtained approval for the registration application of Shaoyao Gancao Tang Granules from China's National Medical Products Administration.The drug is used for various spasm and pain conditions caused by insufficiency of yin and blood and malnourishment of the sinews and vessels that manifests as leg and feet spasms andabdominal pain, according to a Monday filing.

HKG:2196SHA:600196
Asia

Fosun Pharma's Vaccine Unit Submits Hong Kong Listing Application

Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) vaccine unit, Fosun Adgenvax, has submitted an application for a Hong Kong listing, according to a Friday Hong Kong bourse filing.The company plans to issue H-shares representing no more than 25% of its enlarged share capital, with an overallotment option of up to 15% of the initial offering size.Fosun Pharma said Fosun Adgenvax is expected to remain a subsidiary after the listing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Passes GMP Inspection

Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) subsidiary, Shanghai Henlius Biotech (HKG:2696), passed a drug GMP or good manufacturing practice inspection, according to a Shanghai bourse filing on Thursday.The Shanghai Municipal Medical Products Administration made the inspection at Henlius' manufacturing facility in Songjiang District, which produces the breast cancer drug Hanbeiyou or pertuzumab injection.The company was found to be compliant with GMP requirements.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.

HKG:2196HKG:2696SHA:600196
Asia

Fosun Pharma Gets China Nod to Trial HLX3902 Injection

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through its subsidiary Shanghai Henlius Biotech (HKG:2696), received approval from China's National Medical Products Administration for the clinical trials of HLX3902 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for metastatic castration-resistant prostate cancer and other advanced solid tumors.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.

HKG:2196HKG:2696SHA:600196
Asia

Fosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical to Invest 414 Million Yuan in Xingyao Kunze's Series B Funding Round

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through subsidiary Fosun Pharma Industry, plans to invest 414.4 million yuan to participate in the Series B financing of Xingyao Kunze, according to a Wednesday filing on the Shanghai bourse.Xingyao Kunze develops drugs for liver diseases. Its pipeline products are HT-101 and HT-102, and the combination of these drugs.After the completion of the funding round, Fosun Pharma Industry is expected to own 20.9% of Xingyao Kunze.The pharmaceutical company's Hong Kong shares fell by less than 2% during the afternoon trade.

HKG:2196SHA:600196
Asia

Fosun Pharma Gets Registration Nod for Infection Drug in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.

HKG:2196SHA:600196
Asia

Fosun Pharma Secures $60 Million Option for Alzheimer's Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.

HKG:2196SHA:600196
Asia

Fosun Pharma's Unit's Registration Application for Blood Stasis Syndrome Drug Accepted in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Approval for Antidepressant Application

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit's drug registration application for Venlafaxine Hydrochloride Sustained-release Tablets obtained approval from China's National Medical Products Administration.The approved indication for the drug, developed by Fosun Pharma (Xuzhou), is to treat depression and generalized anxiety disorder, according to a Friday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Acute Heart Failure Drug Registration

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application for the Sodium Nitroprusside Injection was approved by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approved indication is for hypertensive emergencies and acute heart failure.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology obtained approval for a phase I/II clinical trial of FKC289 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug will be tested for the treatment of primary light chain amyloidosis and membranous nephropathy.The subsidiary will begin the trial once conditions are met.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod to Register Analgesia Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application of Flurbiprofen Axetil Injection was approved by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indication is for post-surgical and cancer-related analgesia.

HKG:2196SHA:600196

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2196 in your portfolio
WheelAI
WheelAI
Analyze HKG:2196 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2196